Abstract
【Objective】Chronic antibody-mediated rejection (CAMR) is among the most important factors that affect the outcome of kidney allograft. de novo donor-specific anti-HLA antibodies (DSA) have been reported to be related to CAMR.
However, it remains still unclear about the relationship between the characteristics of de novo DSA and CAMR.The aims of the present study were to (1) clarify the de novo incidence rate and (2) investigate the relationship between the characteristics of de novo DSA and CAMR in kidney transplant recipients
【Methods】One hundred and forty-five patients who had undergone kidney transplantation from 2000 to 2015 were screened for HLA antibodies. They were detected by using Luminex single antigen beads (One Lambda Inc.) with LABScan 100.
【Results】DSA after kidney transplantation were detected in 54 patients (37%), and de novo DSAs were demonstrated in 47 patients of these 54 (87%).
In 47 patients with de novo DSA, 40 (85%) were found to have HLA-DQ DSA. Of these 40 patients, 32 (80%) were diagnosed with biopsy-proven acute AMR or CAMR 6 months or later posttransplant and 4 (12.5%) lost their kidney allografts.
【Conclusion】De novo HLA-DQ DSA were detected more frequently compared with HLA-class I or -DR DSA in kidney transplant recipients with CAMR. Screening for HLA-DQ DSA after kidney transplantation seems favorable to obtain better long-term outcomes of kidney allografts.
